California Healthcare | Services & Community BenefitNavigation
Community members are invited to join a free showing of the award-winning film, Forks Over Knives, at Mills-Peninsula Medical Center, clinic building, Auditorium 1, June 25 at 7 p.m., says Debra Shapiro, M.D., a Mills-Peninsula OB/Gyn.
The 96-minute film will be followed by a Q&A discussion with Katie Mae, M.S., a nutritionist and culinary instructor who specializes in plant-based and sugar-free cooking. Light refreshments will be served. Read More about Movie Night at Mills-Peninsula June 25: Forks Over Knives
Designed to rate how well hospitals protect patients from accidents, errors, injuries and infections, the latest Hospital Safety Score honored Mills-Peninsula with an “A,” its top grade in patient safety. The Hospital Safety Score is compiled under the guidance of the nation’s leading experts on patient safety and is administered by The Leapfrog Group (Leapfrog), an independent industry watchdog. The first and only hospital safety rating to be peer-reviewed in the Journal of Patient Safety, the Score is free to the public and designed to give consumers information they can use to protect themselves and their families when facing a hospital stay. Read More about Mills-Peninsula Earns ‘A’ Grade in Spring 2014 Hospital Safety Score
Mills-Peninsula Health Services has received a designation for providing specialized care to geriatric patients. The program is called NICHE (Nurses Improving Care for Healthsystem Elders), and provides training for nurses and hospital leadership in issues related to caring for older patients.
The NICHE initiative started at Mills-Peninsula with a grant from the Mills-Peninsula Hospital Foundation to support the specialized training. Jason Overby, an advanced practice nurse who specializes in geriatric care, spearheaded the program after recognizing the need. Read More about Mills-Peninsula Achieves Geriatric Care Designation
For the fourth year in a row, Mills-Peninsula Health Services has received the American Heart Association/American Stroke Association’s Stroke Gold Plus award, part of the Get With The Guidelines stroke prevention program. The award recognizes Mills-Peninsula for treating stroke patients with 85 percent or higher compliance to American Heart Association/American Stroke Association standards of care for at least two consecutive years and achieving 75 percent or higher compliance with seven of 10 stroke quality measures in the Get With The Guidelines program. Read More about Mills-Peninsula Receives Fourth Consecutive Stroke Quality Award
Thanks to generous support from donors, the Mills-Peninsula Women’s Center has replaced all digital mammography units with digital breast tomosynthesis, providing 3D mammography for breast cancer screenings at no extra cost to patients.
“Digital breast tomosynthesis allows cross sectional views of breast tissue that can uncover tumors that would not be visible on standard mammograms,” says Harriet Borofsky, M.D., medical director of imaging at Mills-Peninsula’s Women’s Center. In fact, a large study from Norway published in the Journal of the American College of Radiology in January 2013, shows that digital breast tomosynthesis improved the overall cancer detection rate by 27 percent and increased the detection of invasive breast cancer by up to 40 percent.
This week Google announced its latest innovation: a smart contact lens developed to help people with diabetes monitor their glucose levels. Patients are more likely to comply with monitoring that does not require frequent pin (lancet) pricks for blood samples, and maintain better health as a result.
Google says that the lens, currently in prototype form, will use a wireless chip and a tiny glucose sensor planted between two layers of material designed for soft contact lenses to measure glucose levels in tears. The lens will use miniature lights to warn the diabetic person if their glucose readings reach a dangerous level. Google reports that they have “completed clinical research studies that explore tear/blood glucose correlation and test lens functionality and comfort.”
Dr. David Klonoff, medical director at the Diabetes Research Institute at Mills-Peninsula Health Services, worked with Google on a clinical study to evaluate that ability to detect glucose in tears. He was Principal Investigator and co-author of the protocol for the first study in the Google contact lens project.
“We measured tear glucose levels with a unique sampling system and a special measuring method that were developed by Google for very small volumes and very low glucose concentrations. We compared tear glucose levels with blood glucose levels to see how closely these two measurements tracked,” Dr. Klonoff explains.
Test results are still being analyzed by Dr. Klonoff’s team but he reports that he is optimistic about the outcomes and eventual benefit to patients.
“It was exciting working with scientists from Google and to collaborate with such a dynamic creative company. They do not let any barriers stand in their way. I have been following the work of the Google scientists for many years and they are extremely creative,” Dr. Klonoff says.
Read the official Google blog, Introducing Our Smart Contact Lens Project by Brian Otis and Babak Parviz, project co-founders.
He founded the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Health Services to facilitate development of new devices and drugs for people with diabetes. He has chaired the scientific advisory board for developing the first FDA-approved insulin patch pump and participated in development of the first FDA-approved dedicated diabetes telemedicine system, the first FDA-approved inhaled insulin, and the first three FDA-approved incretin drugs for diabetes. He recently published his findings in the New England Journal of Medicine as the lead investigator for the first-ever randomized controlled multicenter trial of the world’s first artificial pancreas product for outpatient use.
A new treatment that effectively targets cancer cells is offering pain relief, improved quality-of-life and extended survival time for men with late-stage prostate cancer that has spread to the bones.
Mills-Peninsula’s Dorothy E. Schneider Cancer Center has introduced this new cancer treatment, Xofigo (Radium-223 dichloride), for patients with advanced-stage prostate cancer that has metastasized to the bones, but not other organs. Xofigo was approved by the U.S. Food and Drug Administration (FDA) in May 2013 for treatment of metastatic castration-resistant prostate cancer. Mills-Peninsula’s cancer center is among the first in the Bay Area to offer this new treatment.
“This drug has very low toxicity and has the potential to create comfort in men who are suffering, and it may even prolong their lives,” says Stephen Weller, M.D., a Mills-Peninsula radiation oncologist. “It is an important drug — similar to other types of radiation treatment but more effective.”